MRK - Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer Stock Soars | Benzinga
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
The updated efficacy and safety data was presented at the ESMO Virtual Plenary session.
Related: Cancer Focused Immutep’s Stock Soars On Tuesday – Here’s Why.
The investigational immuno-oncology (IO) combination utilizing efti and Keytruda achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable patients) and a disease control ...